Issue 9, 2020

Histone lysine specific demethylase 1 inhibitors

Abstract

LSD1 plays a pivotal role in numerous biological functions. The overexpression of LSD1 is reported to be associated with different malignancies. Over the last decade, LSD1 has emerged as an interesting target for the treatment of acute myeloid leukaemia (AML). Numerous researchers have designed, synthesized, and evaluated various LSD1 inhibitors with diverse chemical architectures. Some of these inhibitors have entered clinical trials and are currently at different phases of clinical evaluation. This comprehensive review enlists recent research developments in LSD1 targeting pharmacophores reported over the last few years.

Graphical abstract: Histone lysine specific demethylase 1 inhibitors

Article information

Article type
Review Article
Submitted
30 Apr 2020
Accepted
08 Jul 2020
First published
31 Jul 2020

RSC Med. Chem., 2020,11, 969-981

Histone lysine specific demethylase 1 inhibitors

S. Mehndiratta and J. Liou, RSC Med. Chem., 2020, 11, 969 DOI: 10.1039/D0MD00141D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements